| Document |
Document Title |
|
WO/2023/132842A1 |
A method for treating an early-stage microbial infection comprising determining whether a subject is exposed to a coronavirus, such as SARS-CoV-2, or suspected of being exposed to a coronavirus, or exposed to another infected with or sus...
|
|
WO/2023/127600A1 |
The present invention addresses the problem of providing a novel drug for treating SITH-1-associated diseases. The problem is solved by a drug for treating SITH-1-associated diseases, the drug containing a cholinergic agonist as an activ...
|
|
WO/2023/127907A1 |
The present invention addresses the problem of avoiding an immune response caused by gene transfection. The present inventors have found, after intensive studies to solve the above problem, that it is possible to avoid apoptosis due to i...
|
|
WO/2023/128918A1 |
The invention relates to a process including feeding gas system for preparing dry powder inhalation compositions in the treatment of chronic obstructive pulmonary disease (COPD), asthma and other obstructive airway diseases.
|
|
WO/2023/126028A2 |
Provided in the present invention are a microbial strain of Lachnospiraceae, a drug for preventing and/or treating at least one disease of tumors, metabolic diseases, diabetes, autoimmune diseases, infectious diseases, central nervous di...
|
|
WO/2023/129050A1 |
The present invention relates to a pharmaceutical composition comprises a granulate comprising empagliflozin or salts thereof and linagliptin or salts or crystalline polymorph thereof, wherein the granulate is obtained by hot melt extrus...
|
|
WO/2023/125112A1 |
Provided are an antagonist composition and application thereof in the preparation of a drug for treatment of sleep disorders with co-morbid psychiatric disorders; said antagonist composition comprises a CRH receptor antagonist and a glut...
|
|
WO/2023/129946A1 |
Dosing methods and regimens and various dosage forms including formulations and kits for treating fever in children are provided. One dosing regimen or method for treating a febrile child comprises administering a dose to the child, the ...
|
|
WO/2023/125519A1 |
The present invention relates to a new application of an expression promoter of a plant-derived alkaline phosphatase, used primarily for preparing everyday products or medicines for promoting hair growth and/or preventing and treating ha...
|
|
WO/2023/128893A1 |
The present invention relates to buccal film formulations developed for use in various conditions such as buccal infection, wound, etc. The invention also relates to a method used in the preparation of the buccal film formulations of the...
|
|
WO/2023/123216A1 |
Provided is a use of vesicles in the preparation of a drug for treating lung diseases. The vesicles are induced vesicles and can be used for treating/preventing various lung diseases or disorders. At present, there is a lack of a clear m...
|
|
WO/2023/127961A1 |
According to the present invention, provided is a composition for inducing satiety or suppressing overeating. This invention provides a GABA-containing composition for inducing transient satiety in a subject. This invention also provid...
|
|
WO/2023/128722A1 |
The present invention relates to a composition for treating ALK inhibitor-resistant non-small cell lung cancer comprising a cysteine deaminase (CDA) inhibitor and, more specifically, to a composition for treating ALK inhibitor-resistant ...
|
|
WO/2023/129892A1 |
The present invention is directed to an aerosol foam composition comprising an active pharmaceutical ingredient (API) with low water solubility an emulsifier blend containing cetearyl alcohol, dicetyl phosphate, and ceteareth-10 phosphat...
|
|
WO/2023/127012A1 |
Provided is a therapeutic drug that is useful for treating aneurysm. A medicinal composition for treating and/or preventing aneurysm that comprises at least one of the following agents i) to iii) as an active ingredient. i) An agent ...
|
|
WO/2023/128464A1 |
The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising a carnitine acylcarnitine carrier (CAC) inhibitor and a peroxisomal beta oxidation inhibitor. In the present invention, it has be...
|
|
WO/2023/129502A1 |
Disclosed in certain embodiments a parenteral formulation comprising a compound, of Formula (I) as disclosed, herein and a pharmaceutically acceptable excipient, wherein the formulation maintains at least 90%. of the compound after accel...
|
|
WO/2023/125535A1 |
A compound having a deuterated peptidomimetic structure and a pharmaceutical composition containing same, and a use of the composition in prevention and/or treatment of diseases caused by RNA virus infection sensitive to a 3CL protease i...
|
|
WO/2023/128048A1 |
The present invention relates to a cancer therapeutic combination comprising a cancer-targeting trans-splicing ribozyme and an immune checkpoint inhibitor. The ribozyme of the present invention exhibits cancer cell-specific expression, i...
|
|
WO/2023/123959A1 |
An aluminum-manganese composite nanocrystal, and a preparation method therefor and the use thereof. The method for preparing the aluminum-manganese composite nanocrystal comprises: step 1, mixing an aluminum salt solution, a manganese sa...
|
|
WO/2023/130028A1 |
This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment o...
|
|
WO/2023/124973A1 |
Disclosed in the present invention is a method for treating tumors by means of combining an exogenous antigen with a therapeutic agent, which belongs to the technical field of gene therapy. Disclosed in present invention is a composition...
|
|
WO/2023/127909A1 |
Provided is a therapeutic drug that is useful for treating arterial aneurysm. The pharmaceutical composition for treating and/or preventing arterial aneurysm comprises at least one of the following chemical agents i) to iii) as an acti...
|
|
WO/2023/128686A1 |
The present invention relates to a compound represented by chemical formula 1 in the present specification, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising a chemotherapeutic agent, wherein the ...
|
|
WO/2023/118238A1 |
The invention relates to compositions for use in a method of treatment of B cell acute lymphoblastic leukemia (B-ALL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL) or T-cell acute lymphoblastic leukemia (T-ALL). the co...
|
|
WO/2023/117914A1 |
Cyclopentathiophene carboxamides of formula (I), wherein R1, R2, R3, R4, and n are as defined in the description and the claims, and pharmaceutically acceptable salts thereof can be used in methods for the treatment of diseases which can...
|
|
WO/2023/120696A1 |
The present invention provides a compound that exhibits an anticancer effect based on Checkpoint Kinase 1 (CHK1) inhibition. It is discovered that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof has a ...
|
|
WO/2023/116374A1 |
Provided is a herpes zoster vaccine composition. The composition comprises a varicella-zoster virus antigen and a composite adjuvant, wherein the composite adjuvant comprises a CpG oligodeoxynucleotide, QS-21 and a liposome, and the CpG ...
|
|
WO/2023/121670A1 |
Provided herein are suspensions for oral administration comprising a) apremilast, b) a suspending agent, c) a sweetener, d) one or more of a vehicle, a co-solvent, a buffering agent, a preservative, or a combination thereof. Also provide...
|
|
WO/2023/122682A1 |
Compositions comprising donor cells, acceptor cells, and methods involving the same are described herein. In some embodiments, the donor cell is deficient in at least one endogenous function, for instance cytotoxic activity. In some embo...
|
|
WO/2023/122101A1 |
In an embodiment, the present disclosure pertains to a method of reducing cytocidal activity of cells. In some embodiments, the method includes altering eukaryotic elongation factor- 2 kinase (eEF-2K) in a subject and inducing a reductio...
|
|
WO/2023/121394A1 |
The present invention relates to an anti-cancer composition comprising a patient-derived exosome, and the use thereof. The present invention may be utilized in the use of a sensitizer which doubles the effect of a patient-specific cancer...
|
|
WO/2023/118165A1 |
Inventors have shown that salinomycin and its derivatives such as AM23, through lysosomal iron accumulation, reduced proliferation/survival of uveal melanoma cells harboring different genetic background. Accordingly, salinomycin and its ...
|
|
WO/2023/121153A1 |
The present invention relates to use of a vitronectin-derived physiologically active peptide for the treatment of spondyloarthritis. The peptide of the present invention has an activity to inhibit the progression of spondyloarthritis and...
|
|
WO/2023/117879A1 |
The present invention relates to a method for the treatment of FGFR-related bone repair and bone formation and quality impairment. The inventors provide data confirming that abnormal activation of the FGFR3 signaling impairs the bone for...
|
|
WO/2023/115311A1 |
A pharmaceutical composition, comprising: a. a liquid oil; b. at least one pharmaceutically acceptable gelator, wherein the gelator is selected from: a fatty acid, a fatty alcohol, a fatty acid glyceride, a sterol, a sorbitol fatty acid ...
|
|
WO/2023/117768A1 |
The present invention relates to methods for treating a cancer comprising administering to a subject in need thereof an effective amount of a (i) first anti-cancer agent, (ii) an agent sensitizing and/or potentiating the cancer to the fi...
|
|
WO/2023/115757A1 |
An application of adenosine or adenosine monophosphate in preparation of anti-infective drugs. Adenosine or adenosine monophosphate can significantly improve the sensitivity of clinical bacteria such as Escherichia coli, Aeromonas hydrop...
|
|
WO/2023/118126A1 |
The present invention relates to a combination of selective blockers of TASK-1 and TASK-3 channels, in particular substituted imidazo[1,2-a]pyrimidine and substituted imidazo[1,2-a]pyridine derivatives of formula (I) and norepinephrine r...
|
|
WO/2023/118123A1 |
The present invention relates to a combination of a noradrenaline reuptake inhibitor and α2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular substituted heterocyclic carboxamides of formula (I) for the treatment and/or proph...
|
|
WO/2023/116671A1 |
Provided is a method and a medicament for treating amyotrophic lateral sclerosis (ALS) in a subject in need thereof, comprising administering to the subject an effective amount of one or more active agents selected from the group consist...
|
|
WO/2023/118893A1 |
There is provided herein compounds of formula I : (I) and pharmaceutically-acceptable salts and/or detectably-labelled derivatives thereof, wherein RA, RB, X, Y, n and m have meanings as provided in the description, together with formula...
|
|
WO/2023/119230A1 |
Provided are compositions comprising (1) a physiologically effective amount (e.g., a cosmetically effective amount or therapeutically effective amount) of a coagulation pathway modulation component (CP-MC), which modulates a protein C ac...
|
|
WO/2023/117855A1 |
The present invention relates to a method for the treatment of FGFR-related bone repair and bone formation and quality impairment. The inventors provide data confirming that abnormal activation of the FGFR3 signaling impairs the bone for...
|
|
WO/2023/121103A1 |
The present invention relates to an agent capable of inhibiting the activity or enhancing the expression of various cancer-related RNAs in TAMs and cancer cells, and to a dual target drug delivery system capable of binding to both macrop...
|
|
WO/2023/116283A1 |
Provided is an Enterococcus lactis with the deposit number of CCTCC NO: M20211220, which is deposited in the China Center for Type Culture Collection. The provided Enterococcus lactis of CCTCC NO: M20211220 can still ensure a survival ra...
|
|
WO/2023/118085A1 |
The present disclosure relates to methods of treating a brain tumour or a neuroblastoma in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a substituted azaquinolone com...
|
|
WO/2023/109836A1 |
Disclosed is an ultrasonically-enhanced continuous and large-scale production method for nano-formulations. Specifically disclosed is a preparation system for continuous production of nano-formulations, comprising (a) a first pipe, (b) a...
|
|
WO/2023/109906A1 |
A pharmaceutical composition for inflammatory skin diseases, a preparation method therefor, and a use thereof in preparation of drugs for treating and/or preventing immunological, inflammatory and autoimmune diseases. The pharmaceutical ...
|
|
WO/2023/114264A1 |
Disclosed are methods, uses, and combinations for treating high-risk metastatic hormone-sensitive prostate cancer, the methods, uses, and combinations including the administration of (i) a CDK4 and 6 inhibitor or a pharmaceutically accep...
|
